Rigor Reviewed

Rigor-Reviewed Manuscript

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.

Name: Αlpha¹ Rigor Record — Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
Item: Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
Rating: 94
Author: Αlpha¹

Wainberg ZA, Manji GA, Bahary N, Ulahannan SV, Pant S, Spigel DR, Uboha NV, Oberstein PE, Saeed A, Beagle B, Kim JY, Wang N, Weeder B, Shitole S, Mrouj K, Scott JR, Ensign LG, DiRenzo DM, Walters MJ, Wu W, Kaplan A, Cho S, Kabbarah O, O'Reilly EM

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 2 high issues for “Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Study-design details incomplete (controls, blinding, power)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This phase 1b trial is methodologically sound for an early-phase oncology study, with clear scientific rationale, detailed reporting of demographics, ethics approvals, and a concrete data availability statement. The main weaknesses are the open-label design, lack of formal power analysis, and minor reporting gaps in statistical assumptions and exact p-values. Overall, the paper is robust and transparent, with only minor issues that do not undermine its conclusions.

Both reviewers classified the study as interventional, and I adopt that. The evaluation covered all eight dimensions; several sub-criteria were marked not applicable (e.g., species/strain, housing, IACUC, controls, independent replication) due to the human clinical trial context. The statistics verification covered only a subset of tests (8 reported with test statistics/CI), so the absence of errors does not confirm overall statistical correctness. The reviewers diverged on study design (warn vs. pass); I weighed the open-label design and lack of formal power analysis as genuine limitations, leading to a warn.

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 8 tests: 8 consistent, 0 inconsistent; 6 recomputed directly from the reported test statistics, 2 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites multiple prior studies on CD73, adenosine signaling, and the failure of existing therapies, establishing the scientific foundation. The rationale for targeting CD73 with quemliclustat is clearly articulated, and the study objectives follow logically. Limitations of prior transcriptional signatures are acknowledged, and the paper addresses them by proposing NR4A family expression as a more robust biomarker.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on CD73/adenosine biology and the need for new therapies in mPDAC, and it provides a logical rationale linking the premise to the study objectives.

Evidence

paraphrase[Introduction, paragraph 1]

“The ectonucleotidase CD73 is a key enzyme involved in the production of extracellular adenosine from adenosine triphosphate (ATP).”

paraphrase[Introduction, paragraph 2]

“Quemliclustat is a potent and selective small‑molecule inhibitor of soluble and cell‑bound CD73 that is being studied in multiple tumor types.”

direct quote[Introduction, paragraph 2]

“However, these transcriptional signatures have limited predictive value, in part because they may not adequately reflect the cellular heterogeneity in the TME.”